FXYD3 and breast carcinoma: Using spatial RNA sequencing annotated cancerous tissue using a combination of established breast cancer markers, including FXYD3, human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), MKI67, topoisomerase II alpha (TOP2A), and epithelial cell adhesion molecule (EPCAM) (Figure 1J–K), CD74 (MDSC marker; Figure 1L), CD68 (macrophage marker; Figure 1M), and LAMP1 (Figure 1N).